After considering the feedback from consultation, the Evaluation Committee has prepared a Final Evaluation Determination (FED) on eculizumab for treating atypical haemolytic uraemic syndrome (aHUS) and submitted it to the Institute.

The FED has been sent to consultees for this evaluation who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FED has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FED may be used as the basis for the Institute's guidance on the use of the evaluated technology in the NHS in England and Wales.

Please note that the appeal period for this evaluation will close at 5pm on 11 December 2014.

• Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: final evaluation document
• Atypical haemolytic uraemic syndrome (aHUS) - eculizumab: comments on the evaluation consultation document